Literature DB >> 11535817

The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species.

A A Ruefli1, M J Ausserlechner, D Bernhard, V R Sutton, K M Tainton, R Kofler, M J Smyth, R W Johnstone.   

Abstract

Many chemotherapeutic agents induce mitochondrial-membrane disruption to initiate apoptosis. However, the upstream events leading to drug-induced mitochondrial perturbation have remained poorly defined. We have used a variety of physiological and pharmacological inhibitors of distinct apoptotic pathways to analyze the manner by which suberoylanilide hydroxamic acid (SAHA), a chemotherapeutic agent and histone deacetylase inhibitor, induces cell death. We demonstrate that SAHA initiates cell death by inducing mitochondria-mediated death pathways characterized by cytochrome c release and the production of reactive oxygen species, and does not require the activation of key caspases such as caspase-8 or -3. We provide evidence that mitochondrial disruption is achieved by means of the cleavage of the BH3-only proapoptotic Bcl-2 family member Bid. SAHA-induced Bid cleavage was not blocked by caspase inhibitors or the overexpression of Bcl-2 but did require the transcriptional regulatory activity of SAHA. These data provide evidence of a mechanism of cell death mediated by transcriptional events that result in the cleavage of Bid, disruption of the mitochondrial membrane, and production of reactive oxygen species to induce cell death.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11535817      PMCID: PMC58560          DOI: 10.1073/pnas.191208598

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

Review 1.  Mitochondrial membrane permeabilization during the apoptotic process.

Authors:  E Jacotot; P Costantini; E Laboureau; N Zamzami; S A Susin; G Kroemer
Journal:  Ann N Y Acad Sci       Date:  1999       Impact factor: 5.691

Review 2.  Mitochondrion as a novel target of anticancer chemotherapy.

Authors:  P Costantini; E Jacotot; D Decaudin; G Kroemer
Journal:  J Natl Cancer Inst       Date:  2000-07-05       Impact factor: 13.506

Review 3.  Apoptotic pathways: paper wraps stone blunts scissors.

Authors:  D R Green
Journal:  Cell       Date:  2000-07-07       Impact factor: 41.582

4.  Ionizing radiation and chemotherapeutic drugs induce apoptosis in lymphocytes in the absence of Fas or FADD/MORT1 signaling. Implications for cancer therapy.

Authors:  K Newton; A Strasser
Journal:  J Exp Med       Date:  2000-01-03       Impact factor: 14.307

5.  Granzyme B short-circuits the need for caspase 8 activity during granule-mediated cytotoxic T-lymphocyte killing by directly cleaving Bid.

Authors:  M Barry; J A Heibein; M J Pinkoski; S F Lee; R W Moyer; D R Green; R C Bleackley
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

6.  Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.

Authors:  V M Richon; T W Sandhoff; R A Rifkind; P A Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

7.  Genetic analysis of chemoresistance in primary murine lymphomas.

Authors:  C A Schmitt; C T Rosenthal; S W Lowe
Journal:  Nat Med       Date:  2000-09       Impact factor: 53.440

Review 8.  Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells.

Authors:  P A Marks; V M Richon; R A Rifkind
Journal:  J Natl Cancer Inst       Date:  2000-08-02       Impact factor: 13.506

9.  Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.

Authors:  L M Butler; D B Agus; H I Scher; B Higgins; A Rose; C Cordon-Cardo; H T Thaler; R A Rifkind; P A Marks; V M Richon
Journal:  Cancer Res       Date:  2000-09-15       Impact factor: 12.701

10.  Initiation of apoptosis by granzyme B requires direct cleavage of bid, but not direct granzyme B-mediated caspase activation.

Authors:  V R Sutton; J E Davis; M Cancilla; R W Johnstone; A A Ruefli; K Sedelies; K A Browne; J A Trapani
Journal:  J Exp Med       Date:  2000-11-20       Impact factor: 14.307

View more
  158 in total

1.  A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia.

Authors:  Tapan M Kadia; Hui Yang; Alessandra Ferrajoli; Sirisha Maddipotti; Claudia Schroeder; Timothy L Madden; Julianne L Holleran; Merrill J Egorin; Farhad Ravandi; Deborah A Thomas; Willie Newsome; Blanca Sanchez-Gonzalez; James A Zwiebel; Igor Espinoza-Delgado; Hagop M Kantarjian; Guillermo Garcia-Manero
Journal:  Br J Haematol       Date:  2010-04-29       Impact factor: 6.998

Review 2.  Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus.

Authors:  Dan P Christensen; Mattias Dahllöf; Morten Lundh; Daniel N Rasmussen; Mette D Nielsen; Nils Billestrup; Lars G Grunnet; Thomas Mandrup-Poulsen
Journal:  Mol Med       Date:  2011-01-25       Impact factor: 6.354

3.  The effect of combined treatment with cisplatin and histone deacetylase inhibitors on HeLa cells.

Authors:  Ke Long Jin; Jeong-Yeol Park; Eun Joo Noh; Kwang Lae Hoe; Joo Hak Lee; Jong-Hyeok Kim; Joo-Hyun Nam
Journal:  J Gynecol Oncol       Date:  2010-12-31       Impact factor: 4.401

4.  Efficacy of vorinostat in a murine model of polycythemia vera.

Authors:  Hajime Akada; Saeko Akada; Ajeet Gajra; Alicia Bair; Stephen Graziano; Robert E Hutchison; Golam Mohi
Journal:  Blood       Date:  2012-03-09       Impact factor: 22.113

5.  Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells.

Authors:  Eun-Taex Oh; Moon-Taek Park; Bo-Hwa Choi; Seonggu Ro; Eun-Kyung Choi; Seong-Yun Jeong; Heon Joo Park
Journal:  Invest New Drugs       Date:  2010-10-27       Impact factor: 3.850

6.  Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.

Authors:  Nilsa Rivera-Del Valle; Tiewei Cheng; Mary E Irwin; Hayley Donnella; Melissa M Singh; Joya Chandra
Journal:  Cancer Chemother Pharmacol       Date:  2018-01-08       Impact factor: 3.333

Review 7.  Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer.

Authors:  Himashinie V K Diyabalanage; Michael L Granda; Jacob M Hooker
Journal:  Cancer Lett       Date:  2012-09-29       Impact factor: 8.679

Review 8.  Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines.

Authors:  Jürgen Sonnemann; Jennifer Gänge; K Saravana Kumar; Cornelia Müller; Peter Bader; James F Beck
Journal:  Invest New Drugs       Date:  2005-03       Impact factor: 3.850

9.  Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma.

Authors:  R K Lindemann; A Newbold; K F Whitecross; L A Cluse; A J Frew; L Ellis; S Williams; A P Wiegmans; A E Dear; C L Scott; M Pellegrini; A Wei; V M Richon; Paul A Marks; S W Lowe; M J Smyth; R W Johnstone
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-30       Impact factor: 11.205

Review 10.  MHC class II regulation by epigenetic agents and microRNAs.

Authors:  Thomas B Tomasi; William J Magner; Jennifer L Wiesen; Julian Z Oshlag; Felicia Cao; Alex N Pontikos; Christopher J Gregorie
Journal:  Immunol Res       Date:  2010-03       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.